Oxford Biomedica (LSE: OXB) is a leading, fully integrated, cell and gene therapy group.

We have built a sector leading viral vector platform, including our lentiviral vector delivery system, LentiVector® platform, which we leverage to develop in vivo and ex vivo products both in-house and with partners. We have also created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases.

Building on our world leading position in lentiviral vectors and success in the adenovirus vector-based AstraZeneca COVID-19 vaccine, we have demonstrated the versatility of our platform and have extended our scope to all types of viral vectors.

Oxford Biomedica has a number of further partnerships, including with Novartis, Juno Therapeutics/ Bristol Myers Squibb, Boehringer Ingelheim, Beam Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen.

Additionally, we have a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, Oxford Biomedica announced that it was broadening its leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business, Oxford Biomedica Solutions, based near Boston, Massachusetts, with Homology Medicines as a 20% owner.